Drug Delivery Business

Taris Biomedical

Taris Bio, Bristol-Myers Squibb launch bladder cancer trial

By

Taris Biomedical has announced the dosing of the first patient in a study of its TAR-200 system plus a programmed immune checkpoint inhibitor for the treatment of muscle-invasive bladder cancer (MIBC). The TAR-200 system continuously delivers the chemotherapy drug gemcitabine in the bladder for multiple weeks. The combination with Bristol-Myers Squibb’s Opdivo (nivolumab) will be […]

Taris Biomedical touts results of bladder cancer treatment study

By

Taris Biomedical today announced positive results from the second arm of a study of its TAR-200 system for the treatment of patients with muscle-invasive bladder cancer (MIBC). The most recent study arm involved 10 patients treated with TAR-200 and yielded positive safety, tolerability and preliminary efficacy data, according to Lexington, Mass.-based Taris. Combined data from […]

Taris Biomedical lands $25m Series B following Bristol-Myers deal

By

One day after announcing a research collab with Bristol-Myers Squibb (NYSE:BMY), Taris Biomedical revealed that it has raised $25 million in a Series B round. Bristol-Myers also contributed to the round, which was led by Yonghua Capital. “We have made substantial progress on our lead programs in bladder cancer and overactive bladder,” president & CEO Purnanand Sarma said […]

Bristol-Myers Squibb taps Taris’ drug-release tech for bladder cancer trial

By

Bristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo, in a Phase Ib muscle invasive bladder cancer trial. As part of the collaboration, Bristol-Myers has also made an equity investment in Lexington, Mass.-based Taris. Taris’ GemRIS system is designed […]

Taris Biomedical closes enrollment in phase Ib trial for drug-device combo

By

Taris Biomedical said today that it closed initial enrollment in its phase Ib clinical trial following positive results. The study is evaluating the safety and efficacy of its drug-device combination product that releases gemcitabine continuously into the bladder for 7 days in patients with muscle invasive bladder cancer. Although the study was slated to enroll […]

Taris launches another Phase I trial for bladder cancer drug-device combo

By

Taris Biomedical said today it is launching a new phase I trial of its TAR-200 gemcitabine releasing intravesical system designed to deliver drugs directly to the bladder for patients with non-muscle-invasive bladder cancer. The phase 1b open-label study is slated to enroll 30 patients to explore whether continuous, local exposure to gemcitabine using TAR-200 is […]

Taris reboots with $32m round for bladder tech

By

A year after dealing its Liris bladder treatment to Allergan in a deal worth up to $588 million, Taris Biomedical raised another $32 million to put toward the implant, which is designed to deliver drugs directly to the bladder. Allergan paid $67.5 million in cash in August 2014 for Liris, a drug-device combination designed to deliver lidocaine to treat […]

Taris Biomedical launches with $15 million financing round

By

Taris Biomedical hit the ground running, raising $15 million from venture fund backers for its launch.

The Lexington-based drug-device developer, which is aiming to leverage lidocaine delivery technology developed at MIT to treat bladder conditions, said (PDF) Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners led the investment round.